RegulatoryEconomic Times
NATCO Pharma receives FDA Establishment Inspection Reprot for Vishakhapatnam plant
Negative-335 sources
GreyOak summary
NATCO Pharma announced it received an Establishment Inspection Report (EIR) from the US FDA regarding its Vishakhapatnam plant. The inspection, conducted between August 17 and 21, resulted in four observations listed on Form-483. The FDA classified the inspection as Voluntary Action Indicated (VAI).
What it affects
- Natco PharmaNATCOPHARMNegative -33
Share price fell 0.35% after FDA report.Rolling sentiment Negative -34
Source
Reported by Economic Times
- Business Today
- BusinessLine
- Economic Times
- Economic Times
- Economic Times
More Natco Pharma news
- Natco Pharma receives EIR from US FDA for Visakhapatnam plantCNBC-TV18 · Company update ·
- Buy Natco Pharma: target of Rs 1065: ICICI SecuritiesMoneycontrol · Company update ·
- Natco Pharma shares rally 9% despite weak Q2 resultsNDTV Profit · Results ·
- Natco Pharma Q2 profit drops 60.8% to ₹202.6 crBusiness Standard · Results ·